News

Number of news items returned: 21 to 40 records of 450

"Helio Lending working on USD 50m cryptocurrency listing on NYSE in 2019 - MD"

29 November 2018

(1994 views)

  "Helio Lending working on USD 50m cryptocurrency listing on NYSE in 2019 - MD"   "Helio Lending, a private Melbourne-based Australian cryptocurrency ...

Helio Lending partners with Crypto Tax Australia

28 November 2018

(2348 views)

  Helio Lending partners with Crypto Tax Australia   Helio Lending today announced an exciting partnership with Crypto Tax Australia, allowing cryptocurrency ...

"Integrative Healthcare set for AUD 15m (USD 11m) ASX listing in 2019, pre-IPO closing soon"

28 November 2018

(2048 views)

  "Integrative Healthcare set for AUD 15m (USD 11m) ASX listing in 2019, pre-IPO closing soon"   "Elevate Group, a Sydney, Australia-based integrated medical ...

"RE PRE IPO CAPITAL RAISING UPDATE - FURTHER $5M SECURED"

27 November 2018

(2439 views)

  "RE: PRE IPO CAPITAL RAISING UPDATE – FURTHER $5M SECURED Elevate Group provides person-centred healthcare through its clinics and the ...

Qponics begins upgrade to pilot algae farm in Brisbane

27 November 2018

(2244 views)

  "Qponics begins upgrade to pilot algae farm in Brisbane   Site preparation (image above) commenced on 26 November to upgrade the existing ...

AgFutures Presentation

21 November 2018

(2200 views)

  AgriTech Commercialisation – An Investment Perspective   Our Managing Director, Dr Mark Rainbird, was the keynote speaker at the recent AgFutures Innovation ...

"Helio Lending secures CASHFLOW INVESTMENTS"

16 November 2018

(2832 views)

  "Helio Lending secures CASHFLOW INVESTMENTS   Helio Lending today announced the imminent acquisition of CASHFLOW INVESTMENTS PTY LTD helping to drive ...

"Qponics seeks AUD 7m (USD 5m) pre-IPO funding ahead of listing by mid-2019 – CEO"

16 November 2018

(2324 views)

  "Qponics seeks AUD 7m (USD 5m) pre-IPO funding ahead of listing by mid-2019 – CEO"   Qponics, a public unlisted Queensland-based Australian ...

Launching in 2019: EMF Performance Centre Nerang

12 November 2018

(5406 views)

  Launching in 2019: EMF Performance Centre Nerang   EMF co-founder Scott walks us through the Nerang facility to explain everything we can ...

BlueMount Capital Appointed as Corporate Advisor by Qponics Limited

09 November 2018

(2924 views)

  BlueMount Capital Appointed as Corporate Advisor by Qponics Limited   BlueMount Capital is pleased to advise that we have been appointed Corporate ...

LAUNCH OF CUTTING EDGE SOLUTION TO COMBAT TOXIC SILICA DUST- Craig Penty from Guarda Group Holdings

07 November 2018

(2908 views)

  LAUNCH OF CUTTING EDGE SOLUTION TO COMBAT TOXIC SILICA DUST - Craig Penty from Guarda Group Holdings   “The fight against death ...

"Fighting Silicosis With Product Innovation"

29 October 2018

(3240 views)

  "Fighting Silicosis With Product Innovation"   "There are increasing reports of chronic illness, including silicosis and even deaths of trades people in ...

Congratulations, News and Events - Funding Strategies Connect October 2018

29 October 2018

(2993 views)

Congratulations, News and Events - Funding Strategies Connect October 2018     Dear Reader, Welcome to the October 2018 edition of Funding Strategies Connect! We ...

EMF Opens Upper Coomera Location

24 October 2018

(3602 views)

    EMF Opens Upper Coomera Location "We opened our latest edition to the EMF Group in September being EMF Performance Centre Upper ...

Walker Capital Closes Round 2

18 October 2018

(3615 views)

    Walker Capital Closes Round 2 "On behalf of Walker Capital, I am excited to announce the completion of Round 2 of ...

Conference report: SuperReturn Asia 2018, Hong Kong

16 October 2018

(3165 views)

  Conference report: SuperReturn Asia 2018, Hong Kong     BlueMount Capital's Director, M&A, Flora Mok, attended the SuperReturn Asia Conference at the JW ...

An excellent night at the HKABA QLD Business Awards!

05 October 2018

(3709 views)

  An excellent night at the HKABA QLD Business Awards!   BlueMount Capital was honoured and delighted to be a finalist in the ...

Award Finalist and Introductions - Funding Strategies Connect September 2018

28 September 2018

(3864 views)

Award Finalist and Introductions - Funding Strategies Connect September 2018   Dear Reader, Welcome to the September 2018 edition of Funding Strategies Connect! I ...

Walker Capital Launches Affiliate Program

29 August 2018

(4183 views)

  "Become a CPA Affiliate and earn up to 5% per Referral   Partner with Walker Capital and Earn More? Walker Capital values relationships ...

"Engineered stone cutting with prototype Guarda saw for silica dust control"

28 August 2018

(4900 views)

    "This is our new prototype Guarda stone cutting saw. This saw was conceptualised and built in less than 3 weeks ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625